An experimental drug has set a new weight-loss record.
and overweight adults has provided record-breaking weight loss for trial participants — on par with surgical solutions.
Tirzepatide is a once-weekly injection produced by the American pharmaceutical company Eli Lilly and Company (Lilly) that stimulates weight loss
by replicating the effects of natural hormones known as incretins. These hormones regulate digestion-related metabolic processes as well as lowering blood sugar after meals.
Tirzepatide is a synthetic mixture of two incretins called GLP-1 (glucagon-like peptide-1) and GIP (glucagon-like peptide-1).
It is not yet available on the market pending further clinical investigation (glucose-dependent insulinotropic polypeptide).